Ropivacaine long-acting slow-release anesthetic
The "big ball-pack small ball" sustained release system that encapsulates ropivacaine liposomes by sodium alginate microspheres has solved the problem of short analgesic effects and complex preparation of traditional local anesthetics, achieving 5-7 days of analgesic analgesics Duration and postoperative pain management reduce the toxic side effects of the drug on the body.
Patent Information
- Application Number
- CN202410851968.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-28
- Publication Date
- 2024-11-08
AI Technical Summary
The analgesic effects of traditional local anesthetics such as ropivacaine hydrochloride and bupivacaine hydrochloride can only last for several hours and cannot fully inhibit postoperative pain. At the same time, their preparation process is complex, the drug loading volume is low, and the carrier material is biocompatible. The problem is large, leading to the need to develop new long-acting sustained-release local anesthetics.
By premixing ropivacaine liposomes or ropivacaine base liposomes with sodium alginate solution, using electrospinning technology to form microspheres, adjust the diameter and structure of the microspheres, and cross-link them in combination with calcium chloride solution. Prepare a "big ball-pack small ball" sustained release system with sodium alginate microspheres wrapped in ropivacaine liposomes to achieve slow release of the drug.
Achieved a 5-7-day duration of analgesia, prolonged the clinical time of nerve block, slowed down the toxic side effects of high concentrations of ropivacaine hydrochloride on the body, provided a long-term postoperative pain management strategy, and promoted patients Rehabilitation and perioperative safety.
Smart Images

Figure CN118903054A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of medical anesthesia, in particular to a ropivacaine long-acting anesthetic. Background Art
[0002] Since surgical intervention has become popular as an effective clinical treatment, postoperative pain has been an inevitable problem that needs to be solved. Although opioids have shown strong and reliable analgesic efficacy, the associated side effects and the prevalence of the opioid crisis have made it urgent to reduce the use of opioids. In this regard, local anesthetics have become a popular choice for the treatment of postoperative pain due to their rapid onset, low toxicity, and non-addictive nature. However, the analgesic effect of traditional local anesthetic preparations such as ropivacaine hydrochloride and bupivacaine hydrochloride can only last for a few hours, which is far from sufficient to fully suppress postoperative pain.
[0003] Some researchers have tried to make ropivacaine hydrochloride and bupivacaine hydrochloride into sustained-release preparations, but most laboratory-developed preparations still face many challenges, such as complex preparation processes, low drug loading, and biocompatibility issues with carrier materials. Therefore, it is necessary to research and develop new long-acting sustained-release local anesthetics. Summary of the invention
[0004] The present invention first provides a method for preparing a ropivacaine long-acting sustained-release anesthetic, comprising the following steps:
[0005] The ropivacaine liposomes or the ropivacaine base liposomes are added to the sodium alginate solution for premixing;
[0006] Then, the premix filaments were dropped into a calcium chloride solution to form microspheres by electrospinning technology;
[0007] The mixed volume ratio of ropivacaine liposomes or ropivacaine base liposomes to sodium alginate solution is 1-5:10-50; (the preferred ratio is 1:10-50) (a similar ratio between the two may cause the sodium alginate ropivacaine / base liposome mixture to be too viscous and difficult to pass through the dispensing needle)
[0008] The concentration of the sodium alginate solution is as follows: sodium alginate is prepared into a 1-10% (w / v) aqueous solution (preferably 2-5%);
[0009] The concentration of the calcium chloride solution is 1-10 mol / l;
[0010] The parameters of the electrospinning technology are: the voltage of the electrospinning machine is set to 16-18 kV, and the thickness of the dispensing needle is in the range of 21-33 G;
[0011] Microspheres of different diameters can be prepared by adjusting the flow rate of the syringe pump, the inner diameter of the dispensing needle, the voltage, and the distance between the needle and the liquid plane of the CaCl2 solution. The diameter of the prepared long-acting sustained-release anesthetic microspheres is 100-500 μm, and the preferred microsphere diameter is about 200 μm, with uniform size.
[0012] The cross-linking agent calcium chloride solution is preferably an aqueous solution with a concentration of 2-5 mol / l;
[0013] The preparation method of the ropivacaine liposome / ropivacaine base liposome comprises the following steps:
[0014] First, ropivacaine hydrochloride or ropivacaine base (ROP-base) is mixed with lecithin, cholesterol, DPPC and PEG-DSPE in a volatile organic solvent to form a mixture;
[0015] Subsequently, the organic solvent is evaporated to form liposomes containing ropivacaine or ropivacaine base;
[0016] The volatile organic solvent includes, but is not limited to, one or more of ethanol, dichloromethane, chloroform or methanol;
[0017] The weight ratio of ropivacaine hydrochloride or ropivacaine base, lecithin, cholesterol, DPPC and PEG-DSPE can be in the range of (10-40): (20-50): (1-10): (0.2-2): (0.2-2), or more specifically in the range of (20-30): (30-40): (3-7): (0.5-1.5): (0.5-1.5). Exemplarily, these ratios can be 25: 35: 5: 1: 1.
[0018] The lecithin described herein can be derived from natural medicinal lecithin such as egg yolk, soybean, sunflower, rapeseed, peanut or cottonseed, or can be selected from semi-synthetic lecithin, such as hydrogenated lecithin, or a combination thereof. Therefore, the lecithin used in the present invention can be egg yolk lecithin, soybean lecithin, sunflower lecithin, rapeseed lecithin, peanut lecithin or cottonseed lecithin, as long as it meets the standards of medicinal lecithin.
[0019] The full name of PEG-DSPE is 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene glycol)]. For PEG-DSPE, the degree of polymerization of PEG can be 1000-8000, which can be arbitrarily selected, for example, 1000, 2000, 4000, 6000 or 8000.
[0020] The full name of DPPC is 1,2-dipalmitoylphosphatidylcholine, which is a phospholipid.
[0021] The prepared ropivacaine liposome or ropivacaine base liposome can be added with a solvent to form a solution for storage and standby use; wherein the solvent is a phosphate buffer solution, a physiological saline solution or a glucose solution.
[0022] The ropivacaine base is prepared by the following method:
[0023] Ropivacaine hydrochloride is dissolved in an aqueous solvent, such as a buffer, physiological saline or glucose solution, such as a phosphate buffer, etc., with a maximum solubility of 40 mg / ml, and an alkaline solution with a molar concentration of 2-10 times is added to the ropivacaine hydrochloride solution, including but not limited to ammonia water, sodium hydroxide, potassium hydroxide and other liquids to induce alkaline precipitation of ropivacaine.
[0024] The long-acting sustained-release anesthetic provided by the present invention is prepared into liposomes by first preparing ropivacaine hydrochloride or ropivacaine base, then adding sodium alginate solution for premixing, and then dropping polymer filaments into calcium chloride solution to form microspheres by electrostatic spinning technology, so that the ropivacaine base liposomes can be slowly and safely released, and an analgesic duration of 5-7 days is obtained, that is, a longer analgesic effect is obtained, and it is particularly suitable for long-term analgesia after surgical operations. And to a certain extent, the toxic and side effects of high-concentration ropivacaine hydrochloride on the body are slowed down.
[0025] The "big ball encapsulating small ball" anesthetic drug sustained-release system provided by the present invention, in which ropivacaine liposomes are encapsulated by sodium alginate microspheres, has not been invented in previous research literature or patents, and embodies the novelty and innovation of the present invention. The effect of slow drug release is achieved by layer-by-layer encapsulation of sodium alginate microspheres, liposomes and ropivacaine nanoparticles, which can provide an analgesic effect for 5-7 days, prolong the clinical time of nerve block, provide a promising strategy for long-term postoperative pain management, effectively accelerate the patient's postoperative recovery and ensure the patient's perioperative safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 :Sodium alginate microspheres encapsulating ropivacaine base liposomes under light microscopy
[0027] Figure 2 :Blank sodium alginate microspheres under light microscope
[0028] Figure 3 :Ropivacaine base liposomes under TEM electron microscope (500nm)
[0029] Figure 4 :Ropivacaine base liposomes (100nm) under TEM electron microscope
[0030] Figure 5 :Graphic representation of hot plate test results
[0031] Figure 6 :Graphic of acupuncture test results
[0032] Figure 7 : Weight-bearing test result diagram
[0033] Figure 8 : Weight-bearing numerical scoring performance results diagram DETAILED DESCRIPTION
[0034] The following examples and drawings are only used to explain the present invention and are not intended to limit the protection content of the present invention.
[0035] Sources:
[0036] Ropivacaine hydrochloride, ammonia, cholesterol, and PBS solution were purchased from Shanghai Adamas Reagent Co., Ltd.
[0037] Egg yolk lecithin, PEG-DSPG-2000, and DPPC were purchased from Shanghai Yuanye Biochemical Technology Co., Ltd., China.
[0038] Sodium alginate and calcium chloride were purchased from Shanghai McLean Biochemical Technology Co., Ltd.
[0039] Rats: Beijing Weitonglihua Experimental Animal Technology Co., Ltd.;
[0040] Electrospinning machine, PS-TD02-intelligent syringe pump, PS-4+ DC high-voltage power supply, PS-4+ reciprocating bracket: all from Qingdao Pansi Technology Co., Ltd.
[0041] Example 1 Preparation of sodium alginate microsphere-encapsulated ropivacaine liposomes / ropivacaine base liposomes
[0042] 1. Alkalization of Ropivacaine Hydrochloride:
[0043] Crystalline ropivacaine hydrochloride (3 g) was added to 75 mL ddH2O and mixed until completely dissolved.
[0044] 6.52 mL of 14N (10 times molar equivalent) ammonium hydroxide was added to the ropivacaine hydrochloride solution to induce alkaline precipitation of ropivacaine (as shown in the following reaction formula I).
[0045]
[0046] The precipitated base was filtered and extensively washed with ddH2O (centrifugation, removal of supernatant, addition of 10 ml ddH2O and centrifugation three times) to remove any accompanying ammonium hydroxide.
[0047] The resulting powder was lyophilized and stored under desiccant until further use.
[0048] 2. Preparation of Ropivacaine Liposomes / Ropivacaine Base Liposomes
[0049] 5 mg of ropivacaine hydrochloride ROP + 7 mg of egg yolk lecithin + 1 mg of cholesterol + 0.2 mg of DPPC (phosphoglyceride) + 0.2 mg of PEG2000-DSPE (polyethylene glycol 2000) were dissolved in 2 ml of chloroform / ethanol (v:v is 1:1) solution, and rotary evaporated at 30 r / min in a 50°C water bath. After a thin film was formed, 0.5 ml of PBS was added and ultrasonically dispersed and dissolved to form 10 mg / ml ropivacaine liposomes.
[0050] Dissolve 5 mg of ropivacaine base ROP-base + 7 mg of egg yolk phosphatidylcholine + 1 mg of cholesterol + 0.2 mg of DPPC (phosphoglyceride) + 0.2 mg of PEG2000-DSPE (polyethylene glycol) in 2 ml of chloroform / ethanol (v:v is 1:1) solution, and rotary evaporate at 30 r / min in a 50°C water bath. After a thin film is formed, add 0.5 ml of PBS and dissolve it by ultrasonic dispersion to form 10 mg / ml ropivacaine base liposomes.
[0051] Ropivacaine liposomes / ropivacaine base liposomes of different concentrations can be prepared by adjusting the content of added PBS.
[0052] 3. Preparation of sodium alginate microspheres encapsulating ropivacaine liposomes / ropivacaine base liposomes
[0053] First, prepare a 2% (w / v) sodium alginate aqueous solution and stir it under magnetic heating at 60°C for 2 hours to fully dissolve it. After cooling to room temperature, add ropivacaine liposomes / ropivacaine base liposomes solution at a volume ratio of 10:1
[0054] Then, a 2 mol / l CaCl2 solution is prepared and stirred and dissolved at room temperature as a solvent for carrying the microspheres and making them cross-linked. The calcium chloride solution plays the role of carrying and fixing the microspheres. There is no specific requirement for the amount used, as long as it is enough to accommodate the microspheres.
[0055] Assemble the electrospinning machine and set the voltage to 16.5KV. Use a 5ml syringe, connect the inner and outer Luer connectors, plastic hose and 24G dispensing needle to prepare microspheres by electrospraying. The syringe pump flow rate is set to 0.5ml / min. The distance between the dispensing needle and the 2mol / l CaCl2 liquid plane is 5cm. After turning on the high-voltage power supply to start the syringe pump, it can be seen that the sodium alginate liquid has an obvious Taylor cone at the needle. After the droplet is dropped into the CaCl2 solution, the long chain of sodium alginate quickly binds to the CaCl2 solution. 2+ Cross-linking to form microspheres.
[0056] Finally, the obtained microspheres and calcium chloride mixed solution were collected into a centrifuge tube, centrifuged to remove excess calcium chloride solution, and washed with deionized water, repeated three times, and then the supernatant was removed. The microspheres were freeze-dried for storage.
[0057] The diameter of the ropivacaine long-acting sustained-release anesthetic microspheres prepared in this example is 200 μm.
[0058] Figure 1-2 They are sodium alginate microspheres encapsulating ropivacaine base liposomes and blank sodium alginate microspheres under light microscopy. The blank sodium alginate microspheres prepared by high-voltage electrospinning technology show uniform size and smooth surface under light microscopy, while the microspheres encapsulating liposomes can be seen to contain liposome particles under light microscopy. Figure 3-4 The ropivacaine base liposomes (500nm) and ropivacaine base liposomes (100nm) prepared under an electron microscope show that the liposomes have a spherical structure of about 50nm.
[0059] Embodiment 2
[0060] The effect on the sensation and movement of the lower limbs after sciatic nerve block surgery in rats is used to prove that the long-acting sustained-release anesthetic of the present invention can prolong the release of ropivacaine and the analgesic effect.
[0061] In the following experiments, rats were randomly divided into groups, with 5 rats in each group. The weight and age of each group were balanced.
[0062] Depending on the preparation given, the specific groups are as follows:
[0063] Group A: control, ropivacaine liposome (Rop-lipo), 40 mg·mL-1;
[0064] Group B: microspheres prepared from ropivacaine liposomes + sodium alginate solution (Rop-lipo-SA), 40 mg·mL-1;
[0065] Group C: microspheres prepared from ropivacaine base liposomes + sodium alginate solution (Rop-base-lipo-SA), 40 mg·mL-1;
[0066] Group D: ropivacaine hydrochloride solution (Rop-HCl), 40 mg·mL-1;
[0067] Group E: normal saline.
[0068] The ropivacaine liposomes, ropivacaine liposomes + sodium alginate microspheres, and ropivacaine base liposomes + sodium alginate microspheres were all prepared according to Example 1, and the solutions prepared in the four groups were all PBS solutions.
[0069] Specific experimental process:
[0070] 1. Hot plate experiment:
[0071] After injection of preparations of different groups, the rats' toes were in a contracted state when they felt the block on the hot plate (brand UGO BASILE PLANTAR TEST plantar tester model 37370), and they did not feel pain. When the anesthesia effect was insufficient, obvious licking or jumping behavior occurred. The time from the start of thermal stimulation to licking the paw, withdrawing the paw or bouncing was recorded as the rat's paw withdrawal latency (PWL). The center cross of the plantar tester was aligned with the sole of the lower limb of the experimental side of the rat, and the plantar tester would automatically sense and record the time when the rat withdrew its paw. The rats were placed on the plantar tester platform 30 minutes before the test, and the rats were allowed to rest quietly and adapt to the environment. Each rat was tested for basic thermal latency twice before surgery, and each rat was tested for thermal latency 4 times after surgery, with an interval of 5 minutes each time, and the average PWL time of each rat was recorded. In order to protect the animals, the maximum PWL was set to 20 seconds.
[0072] Hot plate test results ( Figure 5 ), it was found that the average PWL of the saline group and each experimental group before surgery was <10s, and the effective threshold of PWL was set to 10s. Among them, the three groups A, B, and C all showed a relatively satisfactory sensory block effect within 6 hours after surgery, and then their sensory block effect continued to decline over time. Among them, the sensory block effect of group A was close to the baseline of 10s after 48 hours, and the effect almost completely disappeared, indicating that the release rate of ropivacaine was faster. Groups B and C still maintained a high-efficiency sensory block effect at 144 hours after surgery (Day 6), indicating that they have excellent analgesic ability, and also show the superior sustained release ability of ropivacaine of the polymer system. Even at 168 hours, groups B and C still had analgesic effects.
[0073] 2. Acupuncture experiment:
[0074] Before the test, rats in each group were placed in a test box (a transparent acrylic box without bottom) on a wire rack to adapt for 3 days, 30 minutes a day. For each test, the animals were first placed in the test box to adapt for 10 minutes, and then the mechanical withdrawal threshold (MWT) of the hind limbs on the experimental side of the animals was tested with a Von Frey analgesic (manufacturer UgoBasile model 37450), with an interval of 5 minutes each time. During the test, the stimulation handle of the mechanical analgesic was held, and the tip of the test needle vertically contacted the test site and slowly applied force until the animal withdrew its foot. The test handle was removed, and the pressure value of the pain stick corresponding to the maximum pressure that caused this reaction (i.e., the mechanical pain threshold of the animal's test site) was recorded. The average pressure of each group of rats was taken for statistics.
[0075] The experimental results show that ( Figure 6 ), according to the results of the control group, MWT < 60 was considered to be almost gone. In group A, the sensory blockade effect was lower than the baseline of 60g after 48h, and the effect almost completely disappeared, indicating that the release rate of ropivacaine was faster. In groups B and C, at 144h after surgery, the sensory blockade effect was still highly effective, indicating the superior analgesic effect, and also indicating the superior sustained release ability of ropivacaine of the polymer material.
[0076] 3. Weight-bearing test results
[0077] Place one of the rat's hind paws on an electronic balance and allow it to bear its own weight. Record the maximum weight that the rat can bear without its ankle touching the balance. When the weight it bears is greater than half of the rat's body weight, the weight-bearing test is considered successful. Each rat is measured five times at each time point, and the average number of successes for each group of rats is recorded for further data analysis.
[0078] The results of the weight-bearing experiment found that ( Figure 7 ), the motor block effect of group E completely disappeared 12h after injection, indicating that the motor function of the unilateral lower limb of rats was restored. The three groups of sustained-release systems, A, B, and C, all had an inhibitory effect on the lower limb activity of the rats on the surgical side within 12h after surgery, but the effects of groups B and C on the movement of the rats on the surgical side were less than those of group A. After 48h, the inhibitory effects of the four experimental groups almost disappeared. After 6h, the number of weight-bearing tests in groups B and C was greater than that in group A, reflecting the slower release capacity of the sustained-release system for ropivacaine and the smaller effect on movement produced thereby.
[0079] 4. Weight-bearing numerical score performance
[0080] Motor function was first assessed using a numerical scoring system based on the animal's behavior at different time points. The scoring system was as follows:
[0081] Normal movement (0 points);
[0082] Weight-bearing activities, inability to fully spread the toes when lifted by the tail (1 point);
[0083] Unable to fully load the movement, unable to spread the toes (2 points);
[0084] Leg weakness, complete inability to bear weight, and complete inability to spread toes (3 points);
[0085] and complete inability to bear weight and flex the toes, with a dragging gait (4 points).
[0086] The results of the weight-bearing numerical scoring showed that ( Figure 8 ), and the motor blockade effect of the ropivacaine hydrochloride group in group D also completely disappeared after 12 hours. The weight-bearing digital score performance is basically consistent with the weight-bearing test results. The average score of group A at 24 hours after surgery was greater than 1, showing a faster sustained release ability and a stronger motor effect. The motor scores of rats in groups B and C were both less than 1 24 hours after surgery, showing that the basic activities of rats were not affected, reflecting the slower release ability of the sustained-release system and the lower motor blockade effect produced thereby.
[0087] During this animal experiment, after the injection of 40 mg·mL-1 ropivacaine hydrochloride solution, 60% of the rats in group D died, and the remaining injected rats also showed varying degrees of decreased mobility and excitability, and no response to stimulation. This is due to the cardiotoxic effect of high-concentration ropivacaine local anesthetic overdose. The symptoms of the rats were relieved 3 hours after the injection of the drug. In other groups, no toxic symptoms occurred, the motility and excitability of the rats did not change, no rats died, all physiological indicators of the rats were normal, and the weight did not decrease. This phenomenon also reflects the sustained release effect of liposome materials, which can slowly and safely release ropivacaine drugs into tissues, reflecting the safety of the sustained release system and its tolerance for larger doses of local anesthetics.
Claims
1. A method for preparing a ropivacaine long-acting sustained-release anesthetic, characterized in that The steps include: adding ropivacaine liposomes or ropivacaine base liposomes into the sodium alginate aqueous solution for premixing; Then, the premix filaments were dropped into a calcium chloride solution to form microspheres by electrospinning technology; The mixed volume ratio of ropivacaine liposomes or ropivacaine base liposomes to sodium alginate solution is 1-5:10-50; The concentration of the sodium alginate aqueous solution is: 1-10%; The concentration of the calcium chloride solution is 1-10 mol / l; The parameters of the electrospinning technology are: the voltage of the electrospinning machine is set to 16-18kV, and the thickness of the dispensing needle is in the range of 21-33G.
2. The method for preparing a ropivacaine long-acting sustained-release anesthetic according to claim 1, wherein The ropivacaine liposomes / ropivacaine base liposomes are prepared by the following method: First, ropivacaine or ropivacaine base is mixed with lecithin, cholesterol, DPPC and PEG-DSPE in a volatile organic solvent to form a mixture; Subsequently, the organic solvent is evaporated to form liposomes containing ropivacaine or ropivacaine base; The volatile organic solvent includes, but is not limited to, one or more of ethanol, dichloromethane, chloroform or methanol.
3. The method for preparing the ropivacaine long-acting sustained-release anesthetic according to any one of claims 1 and 2, wherein The mixed volume ratio of ropivacaine liposomes or ropivacaine base liposomes and sodium alginate solution is 1:10-50; The concentration of the sodium alginate aqueous solution is: 2-5%; The concentration of the calcium chloride solution is 2-5 mol / l.
4. The ropivacaine long-acting sustained-release anesthetic prepared by the method according to any one of claims 1 to 3.
